<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37166260</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-2986</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2023</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of global health</Title><ISOAbbreviation>J Glob Health</ISOAbbreviation></Journal><ArticleTitle>Prevalence and risk factors for long COVID after mild disease: A cohort study with a symptomatic control group.</ArticleTitle><Pagination><StartPage>06015</StartPage><MedlinePgn>06015</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">06015</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7189/jogh.13.06015</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">There is limited data on the prevalence and risk factors for long COVID and few prospective studies with appropriate control groups and adequate sample sizes. We performed a prospective study to determine the prevalence and risk factors for long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We recruited individuals aged &#x2265;15 years who were clinically suspected of having an acute SARS-CoV-2 infection from September 2020 to April 2021. We collected nasopharyngeal swabs three to five days following symptom onset for analysing using reverse transcriptase polymerase chain reaction (RT-PCR). We also collected clinical and sociodemographic characteristics from both SARS-CoV-2 positive and negative participants using structured questionnaires. We followed-up the participants via telephone interview to assess early outcomes and persistent symptoms. For COVID-19 cases, 5D-3L EuroQol questionnaire was used to assess the impact of symptoms on quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We followed 814 participants (412 COVID-19 positive and 402 COVID-19 negative persons). Most (n&#x2009;=&#x2009;741/814) had mild symptoms. Both groups had similar sociodemographic and clinical characteristics, except for the hospitalization rate (15.8% in the COVID-19 positive vs 1.5% in the COVID-19 negative group). One month after disease onset, 122/412 (29.6%) individuals in the COVID-19 positive (long COVID) and 24 (6%) in the COVID-19 negative group reported residual symptoms. In the long COVID group, fatigue, olfactory disorder, and myalgia were the most frequent symptoms in the acute phase. Compared to recovered individuals, older age and having more than five symptoms during the acute phase were risk factors for long COVID. Quality of life was evaluated in 102 out of 122 cases of long COVID, with 57 (55.9%) reporting an impact in at least one dimension of the European Quality of Life 5 Dimensions 3 Level (EQ-5D-3L) questionnaire.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In this prospective study consisting predominantly of individuals with mild disease, the persistence of symptoms after an acute respiratory illness was associated with a diagnosis of COVID-19. Polysymptomatic acute disease and older age were risk factors for long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 by the Journal of Global Health. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Caz&#xe9;</LastName><ForeName>Ana B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Cerqueira-Silva</LastName><ForeName>Thiago</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bomfim</LastName><ForeName>Adriele P</ForeName><Initials>AP</Initials><AffiliationInfo><Affiliation>Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Souza</LastName><ForeName>Gisley L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Bahia School of Medicine and Public Health, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Amanda Ca</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Santa Izabel Hospital, Santa Casa da Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brasil</LastName><ForeName>Michelle Qa</ForeName><Initials>MQ</Initials><AffiliationInfo><Affiliation>Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Nara R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>Department of Health Surveillance/Epidemiological Surveillance, Campo Formoso, Bahia Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khouri</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Clinical and Epidemiological Virology, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dan</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Infectious Disease and Vaccine Research, la Jolla Institute for Immunology (LJI), San Diego (UCSD), California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Disease and Global Public Health, University of California, San Diego (UCSD), California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bandeira</LastName><ForeName>Antonio C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Faculty of Technology and Sciences of Salvador, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Central State Laboratory Lacen/BA, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cavalcanti</LastName><ForeName>Luciano Pg</ForeName><Initials>LP</Initials><AffiliationInfo><Affiliation>Federal University of Cear&#xe1;, Cear&#xe1;, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Christus University Center, Fortaleza, Cear&#xe1;, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barral-Netto</LastName><ForeName>Manoel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barral</LastName><ForeName>Aldina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Research in Immunology, S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Cynara G</ForeName><Initials>CG</Initials><AffiliationInfo><Affiliation>Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boaventura</LastName><ForeName>Viviane S</ForeName><Initials>VS</Initials><AffiliationInfo><Affiliation>Federal University of Bahia, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gon&#xe7;alo Moniz Institute, Fiocruz, Salvador, Bahia, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Glob Health</MedlineTA><NlmUniqueID>101578780</NlmUniqueID><ISSNLinking>2047-2978</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035061" MajorTopicYN="N">Control Groups</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and disclose no relevant interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>11</Day><Hour>9</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37166260</ArticleId><ArticleId IdType="pmc">PMC10173895</ArticleId><ArticleId IdType="doi">10.7189/jogh.13.06015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B.Global Prevalence of Post- Coronavirus Disease (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis. 2022;226:1593-607. 10.1093/infdis/jiac136</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN.Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open. 2021;4:e2111417. 10.1001/jamanetworkopen.2021.11417</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Centers for Disease Control and Prevention. Nearly One in Five American Adults Who Have Had COVID-19 Still Have &#x2018;&#x2019;Long COVID&#x2019;&#x2019;. 2022. Available: https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm. Accessed: 17 September 2022.</Citation></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28:1706-14. 10.1038/s41591-022-01909-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin-Chowdhury Z, Ladhani SN.Causation or confounding: why controls are critical for characterizing long COVID. Nat Med. 2021;27:1129-30. 10.1038/s41591-021-01402-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01402-w</ArticleId><ArticleId IdType="pubmed">34140704</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi MS, Omrani OA, Fawzy NA, Shaar BA, Almamlouk R, Riaz M, et al. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:657-66. 10.1016/j.cmi.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly BD, Gulati G.Long COVID: the elephant in the room. QJM: An International Journal of Medicine. 2022;115:5-6. 10.1093/qjmed/hcab299</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcab299</ArticleId><ArticleId IdType="pmc">PMC8782604</ArticleId><ArticleId IdType="pubmed">34850227</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Peyser ND, Lin F, Knight SJ, Djibo A, et al. Factors Associated with Long Covid Symptoms in an Online Cohort Study. Open Forum Infect Dis. 2023;10:ofad047. 10.1093/ofid/ofad047</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad047</ArticleId><ArticleId IdType="pmc">PMC9945931</ArticleId><ArticleId IdType="pubmed">36846611</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y.Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461-7. 10.1038/s41591-022-01840-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q, Zheng B, Daines L, Sheikh A.Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. Pathogens. 2022;11:269. 10.3390/pathogens11020269</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagib W. Genomahcov &#x2013; Fiocruz [Network Genomics Firocruz]. 2023. Available: http://www.genomahcov.fiocruz.br/. Accessed: 28 April 2023.</Citation></Reference><Reference><Citation>Instituto de Biologia Molecular do Paran&#xe1;. Consultas &#x2013; Ag&#xea;ncia Nacional de Vigil&#xe2;ncia Sanit&#xe1;ria [Consultations &#x2013; National Health Surveillance Agency]. 2023. Available: https://consultas.anvisa.gov.br/#/saude/25351441245202096/. Accessed: 16 June 2023.</Citation></Reference><Reference><Citation>Seegene. AllplexTM SARS-CoV-2 Assay. 2023. Available: https://consultas.anvisa.gov.br/api/consulta/produtos/25351395442202026/anexo/T15632158/nomeArquivo/IFU_80102512493.pdf?Authorization=Guest. Accessed: 28 April 2023.</Citation></Reference><Reference><Citation>Cuschieri S.The STROBE guidelines. Saudi J Anaesth. 2019;13 Suppl 1:S31-4. 10.4103/sja.SJA_543_18</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/sja.SJA_543_18</ArticleId><ArticleId IdType="pmc">PMC6398292</ArticleId><ArticleId IdType="pubmed">30930717</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID. 2022. Available: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/. Accessed: 28 April 2023.</Citation></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. 10.1038/s41598-021-95565-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626-31. 10.1038/s41591-021-01292-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>EuroQol. EQ-5D User Guides &#x2013; EQ-5D. 2022. Available: https://euroqol.org/publications/user-guides. Accessed: 17 September 2022.</Citation></Reference><Reference><Citation>Santos M, Cintra MACT, Monteiro AL, Santos B, Gusm&#xe3;o-filho F, Andrade MV, et al. Brazilian Valuation of EQ-5D-3L Health States. Med Decis Making. 2016;36:253-63. 10.1177/0272989X15613521</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X15613521</ArticleId><ArticleId IdType="pubmed">26492896</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6:e005427. 10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Batiha GE-S, Al-kuraishy HM, Al-Gareeb AI, Welson NN.Pathophysiology of Post-COVID syndromes: a new perspective. Virol J. 2022;19:158. 10.1186/s12985-022-01891-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01891-2</ArticleId><ArticleId IdType="pmc">PMC9548310</ArticleId><ArticleId IdType="pubmed">36210445</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran AV, Jayadevan R, Sashidharan S.Long COVID: An overview. Diabetes Metab Syndr. 2021;15:869-75. 10.1016/j.dsx.2021.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team. R: The R Project for Statistical Computing. 2019. Available: https://www.r-project.org/. Accessed: 28 April 2023.</Citation></Reference><Reference><Citation>Bartoszek A, Walkowiak D, Bartoszek A, Kardas G.Mental Well-Being (Depression, Loneliness, Insomnia, Daily Life Fatigue) during COVID-19 Related Home-Confinement &#x2013; A Study from Poland. Int J Environ Res Public Health. 2020;17:7417. 10.3390/ijerph17207417</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17207417</ArticleId><ArticleId IdType="pmc">PMC7599953</ArticleId><ArticleId IdType="pubmed">33053787</ArticleId></ArticleIdList></Reference><Reference><Citation>Usher K, Bhullar N, Jackson D.Life in the pandemic: Social isolation and mental health. J Clin Nurs. 2020;29:2756-7. 10.1111/jocn.15290</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jocn.15290</ArticleId><ArticleId IdType="pubmed">32250493</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The Psychological Impact of Quarantine and How to Reduce it: Rapid Review of the Evidence. Lancet. 2020;395:912-20. 10.1016/S0140-6736(20)30460-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30460-8</ArticleId><ArticleId IdType="pmc">PMC7158942</ArticleId><ArticleId IdType="pubmed">32112714</ArticleId></ArticleIdList></Reference><Reference><Citation>Strahm C, Seneghini M, G&#xfc;sewell S, Egger T, Leal O, Brucher A, et al. Symptoms compatible with long-COVID in healthcare workers with and without SARS-CoV-2 infection &#x2013; results of a prospective multicenter cohort. Clin Infect Dis. 2022;75:e1011-9. 10.1093/cid/ciac054</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac054</ArticleId><ArticleId IdType="pmc">PMC9383387</ArticleId><ArticleId IdType="pubmed">35090015</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10:761-75. 10.1016/S2213-2600(22)00127-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00127-8</ArticleId><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15:e0240784. 10.1371/journal.pone.0240784</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0240784</ArticleId><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul&#xe8; G, et al. Female gender is associated with &#x201c;long COVID&#x201d; syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28:611.e9-e16. 10.1016/j.cmi.2021.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27:1507-13. 10.1016/j.cmi.2021.05.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Kim S-W, Chang H-H, Kwon KT, Hwang S, Bae S.One Year Follow-Up of COVID-19 Related Symptoms and Patient Quality of Life: A Prospective Cohort Study. Yonsei Med J. 2022;63:499. 10.3349/ymj.2022.63.6.499</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2022.63.6.499</ArticleId><ArticleId IdType="pmc">PMC9171672</ArticleId><ArticleId IdType="pubmed">35619573</ArticleId></ArticleIdList></Reference><Reference><Citation>Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A.COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System. World Neurosurg. 2020;140:49-53. 10.1016/j.wneu.2020.05.193</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.wneu.2020.05.193</ArticleId><ArticleId IdType="pmc">PMC7255736</ArticleId><ArticleId IdType="pubmed">32474093</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, &#xc1; Steig B, Gaini S, et al. Long COVID in the Faroe Islands: A Longitudinal Study Among Nonhospitalized Patients. Clin Infect Dis. 2021;73:e4058-63. 10.1093/cid/ciaa1792</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6:100122. 10.1016/j.lanepe.2021.100122</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100122</ArticleId><ArticleId IdType="pmc">PMC8129613</ArticleId><ArticleId IdType="pubmed">34027514</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. 2022;74:1191-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart S, Newson L, Briggs TA, Grammatopoulos D, Young L, Gill P.Long COVID risk - a signal to address sex hormones and women&#x2019;s health. Lancet Reg Health Eur. 2021;11:100242. 10.1016/j.lanepe.2021.100242</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100242</ArticleId><ArticleId IdType="pmc">PMC8561426</ArticleId><ArticleId IdType="pubmed">34746909</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV.A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102-7. 10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>